Inositol (Myo + D-chiro 40:1)
The women's-wellness ingredient quietly winning the PCOS and fertility category.
Myo-inositol and D-chiro-inositol, dosed at the physiological 40:1 ratio found in human plasma, are the foundation of the modern PCOS, fertility, and metabolic-women's-health category. Quiet evidence base, growing consumer demand.
Inositol is a B-vitamin-like compound that exists in nine stereoisomers, two of which matter for supplements: myo-inositol (the most abundant) and D-chiro-inositol (a downstream metabolite). Both play roles in insulin signaling, ovarian follicle development, and neurotransmitter regulation. The 40:1 myo to D-chiro ratio reflects the natural balance in human plasma and is the dose pattern that gets the strongest results in PCOS and fertility trials.
For the supplement market, this is one of the quieter category-leaders. Inositol doesn't get TikTok virality, but it sits at the center of PCOS and fertility communities, where physician-recommended use has pushed steady consumer demand for over a decade. Meta-analyses support its use for cycle regularity, ovulation, metabolic markers in PCOS, and mood symptoms. The active price point is reasonable, the format options are flexible, and the consumer is highly engaged once you reach them.
The formulation question is mostly about whether to launch a single-ingredient inositol or a more complete women's-metabolic stack. Single-active products work for clinical-channel and OB/GYN-recommended positioning. Stacks combining 40:1 inositol with vitamin D, folate (5-MTHF preferred for PCOS-associated MTHFR polymorphism), N-acetylcysteine, and chromium are the standard build for premium DTC. The 4 g/day dose is bulky. Most products land at 2,000 mg per scoop in a powder format, so the consumer takes one scoop morning and night.
Why Brands Choose Inositol (Myo + D-chiro 40:1)
Owns the PCOS and fertility category
Strong clinical evidence and OB/GYN-recommended status make inositol the default first-line nutritional support in PCOS. Few categories have this kind of physician anchor.
Quiet but durable consumer demand
No TikTok cycle to ride or recover from. Steady search demand for over a decade, growing modestly each year. The kind of base demand that supports a stable product line.
Compatible with most women's-wellness positioning
Cycle support, mood, prenatal preparation, metabolic balance. One active anchors multiple SKUs across a women's-health brand.
Formulation Notes
Working with Inositol (Myo + D-chiro 40:1)
- Standard clinical dose: 4 g/day myo-inositol + 100 mg/day D-chiro-inositol (the 40:1 ratio). Split as 2 g morning, 2 g evening.
- Powder format dominates because of dose volume. Capsules require 6–10 capsules per day, which hurts compliance.
- Myo-inositol is mildly sweet and water-soluble. Easy to drink without masking. D-chiro is more expensive per gram (typically 2–3× myo).
- Pair with 5-MTHF (methylfolate), vitamin D3, and chromium for full metabolic-women's-health stack.
- Avoid 1:1 myo-to-D-chiro ratios despite older trial protocols using them. Current evidence favors the 40:1 physiological ratio.
Dosage Guidance
4 g myo-inositol + 100 mg D-chiro-inositol daily, in two divided doses.
Delivery Forms
Considerations
- GI upset (loose stools, mild bloating) is the most common side effect at full dose. Start with 2 g/day and titrate up.
- Pregnancy use is supported by trial evidence for gestational-diabetes prevention but should always be physician-supervised. Conservative label language is recommended.
- Marketing to PCOS communities is sensitive. Disease claims are off-limits, but structure-function claim language must still resonate authentically.
Regulatory Status
Canada (NPN)
Myo-inositol and D-chiro-inositol are listed in the NHPID and supported by Health Canada monographs. NPN submissions for women's-health claim language follow established paths.
USA (DSHEA)
Sold as dietary ingredients under DSHEA with established structure-function claim history. Avoid disease-specific language ("treats PCOS," "restores fertility") in US labeling.
Common Structure-Function Claims
- Supports menstrual cycle regularity
- Supports healthy ovarian function
- Supports metabolic health in women
- Provides nutritional support for healthy mood
Claim language must be reviewed for your specific product and market before use. Not all claims are permitted in every jurisdiction.
Clinical Evidence & Market Demand
Selected peer-reviewed studies, plus the demand signals we're seeing from founders, retailers, and consumer search behaviour.
Primary literature
Giordano D, Corrado F, Santamaria A, et al. · Menopause · 2011
2 g of myo-inositol twice daily improved insulin sensitivity, HOMA-IR, and lipid profile in postmenopausal women. Bridges inositol use beyond reproductive-age PCOS.
Unfer V, Facchinetti F, Orrù B, et al. · Endocrine Connections · 2017
Systematic review of myo-inositol and D-chiro-inositol in PCOS management. The reference document behind the 40:1 ratio recommendation now standard in clinical practice.
Showell MG, Mackenzie-Proctor R, Jordan V, et al. · Cochrane Database of Systematic Reviews · 2018
Pooled RCT data showing inositol may improve metabolic and ovulation outcomes in PCOS. Cochrane's standard rigor makes this an unusually credible citation.
Nordio M, Proietti E. · European Review for Medical and Pharmacological Sciences · 2012
Established that the 40:1 myo to D-chiro ratio outperforms either alone or in different ratios on metabolic and ovulation endpoints in PCOS.
Market & consumer demand
Inositol's growth is steady and physician-driven. Google search interest has grown roughly 15–20% per year for five consecutive years without a viral spike.
Inositol is the women's-health category's quiet workhorse. There's no TikTok moment in its history; growth has come almost entirely from PCOS patient communities (Reddit's r/PCOS, dedicated Facebook groups), OB/GYN and reproductive-endocrinology recommendations, and word-of-mouth in fertility-focused circles. The brands winning here aren't loud. They're educational, physician-credentialed, and present in clinical channels alongside DTC. Ovasitol (Theralogix) is the historic clinical-channel leader; Wholesome Story, Inositum, and Inofolic each hold pieces of the consumer market. Room remains for new entrants with strong educational content and clinical positioning.
- Examine.com: Inositol: Rated as having strong evidence for PCOS ovulation and metabolic markers, moderate evidence for mood support, weaker for general blood-sugar regulation.
- Androgen Excess and PCOS Society: Position Statement on Inositols: Professional medical society guidance supporting inositol use in PCOS. Useful citation for clinical-channel marketing and HCP-targeted content.
References are provided for educational purposes. Citations do not constitute medical claims or guarantee outcomes. Structure-function claim language must be reviewed for your specific product and market.
Related Services
Related Ingredients
Ready to build with Inositol (Myo + D-chiro 40:1)?
Tell us about your product concept and we'll put together a formulation, sourcing, and manufacturing plan tailored to your brand, format, and market.